BR112016006978A2 - inibidores de tirosina quinase de bruton - Google Patents
inibidores de tirosina quinase de brutonInfo
- Publication number
- BR112016006978A2 BR112016006978A2 BR112016006978A BR112016006978A BR112016006978A2 BR 112016006978 A2 BR112016006978 A2 BR 112016006978A2 BR 112016006978 A BR112016006978 A BR 112016006978A BR 112016006978 A BR112016006978 A BR 112016006978A BR 112016006978 A2 BR112016006978 A2 BR 112016006978A2
- Authority
- BR
- Brazil
- Prior art keywords
- tyrosine kinase
- bruton tyrosine
- disclosed
- conditions
- kinase inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0031—Rectum, anus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
Abstract
1/1 resumo inibidores de tirosina quinase de bruton são aqui revelados compostos que formam ligações covalentes com tirosina-quinase de bruton (btk). também são descritos inibidores irreversíveis de btk. além disso, inibidores reversíveis de btk também são descritos. também são reveladas composições farmacêuticas que incluem os compostos. métodos de utilização dos inibidores de btk são revelados, isoladamente ou em combinação com outros agentes terapêuticos, para o tratamento de doenças ou condições autoimunes, doenças ou condições heteroimunes, câncer, incluindo linfoma e doenças ou condições inflamatórias.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361884888P | 2013-09-30 | 2013-09-30 | |
PCT/US2014/058132 WO2015048689A1 (en) | 2013-09-30 | 2014-09-29 | Inhibitors of bruton's tyrosine kinase |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112016006978A2 true BR112016006978A2 (pt) | 2017-08-01 |
Family
ID=52740746
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112016006978A BR112016006978A2 (pt) | 2013-09-30 | 2014-09-29 | inibidores de tirosina quinase de bruton |
Country Status (20)
Country | Link |
---|---|
US (2) | US9624224B2 (pt) |
EP (1) | EP3052486A1 (pt) |
JP (1) | JP2016531941A (pt) |
KR (1) | KR20160062103A (pt) |
CN (1) | CN105764896A (pt) |
AR (1) | AR097862A1 (pt) |
AU (1) | AU2014324532A1 (pt) |
BR (1) | BR112016006978A2 (pt) |
CA (1) | CA2925124A1 (pt) |
CR (1) | CR20160203A (pt) |
DO (1) | DOP2016000071A (pt) |
EA (1) | EA201690618A1 (pt) |
IL (1) | IL244492A0 (pt) |
MA (1) | MA38961A1 (pt) |
PE (1) | PE20160560A1 (pt) |
PH (1) | PH12016500575A1 (pt) |
SG (1) | SG11201602421VA (pt) |
TN (1) | TN2016000094A1 (pt) |
TW (1) | TW201546061A (pt) |
WO (1) | WO2015048689A1 (pt) |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107898791A (zh) | 2010-06-03 | 2018-04-13 | 药品循环有限责任公司 | 布鲁顿酪氨酸激酶(btk)抑制剂的应用 |
KR20140048968A (ko) | 2011-07-13 | 2014-04-24 | 파마시클릭스, 인코포레이티드 | 브루톤형 티로신 키나제의 억제제 |
JP6105578B2 (ja) | 2011-07-21 | 2017-03-29 | トレロ ファーマシューティカルズ, インコーポレイテッド | 複素環式プロテインキナーゼ阻害剤 |
KR20150032340A (ko) | 2012-07-24 | 2015-03-25 | 파마시클릭스, 인코포레이티드 | 브루톤 티로신 키나제(btk)의 억제제에 대한 내성과 관련된 돌연변이 |
TR201911151T4 (tr) | 2013-03-14 | 2019-08-21 | Tolero Pharmaceuticals Inc | Jak2 ve alk2 inhibitörleri ve bunların kullanım yöntemleri. |
JP6458018B2 (ja) | 2013-07-02 | 2019-01-23 | ファーマサイクリックス エルエルシー | キナーゼ阻害剤としてのプリノン化合物 |
US9885086B2 (en) | 2014-03-20 | 2018-02-06 | Pharmacyclics Llc | Phospholipase C gamma 2 and resistance associated mutations |
CN107021963A (zh) | 2016-01-29 | 2017-08-08 | 北京诺诚健华医药科技有限公司 | 吡唑稠环类衍生物、其制备方法及其在治疗癌症、炎症和免疫性疾病上的应用 |
CN108602834B (zh) * | 2016-02-05 | 2021-01-08 | 北京盛诺基医药科技股份有限公司 | 一种布鲁顿酪氨酸激酶抑制剂 |
JP2020511462A (ja) | 2016-12-03 | 2020-04-16 | ジュノー セラピューティクス インコーポレイテッド | キナーゼ阻害剤との組み合わせで治療用t細胞を使用するための方法および組成物 |
KR101956815B1 (ko) | 2017-02-14 | 2019-03-12 | 한국화학연구원 | 트리아졸로피리다진 유도체, 이의 제조방법 및 이를 유효성분으로 포함하는 브루톤티로신 키나제 활성 관련 질환의 예방 또는 치료용 약학적 조성물 |
US10370381B2 (en) | 2017-02-24 | 2019-08-06 | Gilead Sciences, Inc. | Inhibitors of bruton'S tyrosine kinase |
US10314844B2 (en) | 2017-02-24 | 2019-06-11 | Gilead Sciences, Inc. | Inhibitors of Bruton's tyrosine kinase |
CN108570036A (zh) * | 2017-03-09 | 2018-09-25 | 北京赛林泰医药技术有限公司 | 一种btk抑制剂的多晶型物及其制备方法 |
KR102128018B1 (ko) | 2017-05-12 | 2020-06-30 | 한국화학연구원 | 피라졸로 피리미딘 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 암, 자가면역질환 및 뇌질환의 예방 또는 치료용 약학적 조성물 |
WO2018208132A1 (en) * | 2017-05-12 | 2018-11-15 | Korea Research Institute Of Chemical Technology | Pyrazolopyrimidine derivatives, preparation method thereof, and pharmaceutical composition for use in preventing or treating cancer, autoimmune disease and brain disease containing the same as an active ingredient |
KR102032418B1 (ko) | 2017-06-15 | 2019-10-16 | 한국화학연구원 | 접합 피리미딘 유도체, 이의 제조방법 및 이를 유효성분으로 포함하는 브루톤티로신 키나제 활성 관련 질환의 예방 또는 치료용 약학적 조성물 |
CN109748929A (zh) * | 2017-11-06 | 2019-05-14 | 苏州鹏旭医药科技有限公司 | 一种化合物的制备方法 |
US11161851B2 (en) | 2017-11-06 | 2021-11-02 | Suzhou Pengxu Pharmatech Co. Ltd. | Processes to produce acalabrutinib |
WO2019195753A1 (en) | 2018-04-05 | 2019-10-10 | Tolero Pharmaceuticals, Inc. | Axl kinase inhibitors and use of the same |
CA3095580A1 (en) | 2018-04-13 | 2019-10-17 | Sumitomo Dainippon Pharma Oncology, Inc. | Pim kinase inhibitors for treatment of myeloproliferative neoplasms and fibrosis associated with cancer |
KR20210038906A (ko) | 2018-07-26 | 2021-04-08 | 스미토모 다이니폰 파마 온콜로지, 인크. | 비정상적 acvr1 발현과 연관된 질환을 치료하는 방법 및 그에 사용하기 위한 acvr1 억제제 |
CN110964016B (zh) * | 2018-09-29 | 2021-05-28 | 南京药捷安康生物科技有限公司 | 氨基降茨烷衍生物及其制备方法与应用 |
WO2020167990A1 (en) | 2019-02-12 | 2020-08-20 | Tolero Pharmaceuticals, Inc. | Formulations comprising heterocyclic protein kinase inhibitors |
AU2020242287A1 (en) | 2019-03-21 | 2021-09-02 | INSERM (Institut National de la Santé et de la Recherche Médicale) | A Dbait molecule in combination with kinase inhibitor for the treatment of cancer |
WO2020252397A1 (en) * | 2019-06-12 | 2020-12-17 | Baylor College Of Medicine | Small molecule proteolysis-targeting chimeras and methods of use thereof |
CN111018865B (zh) * | 2019-10-17 | 2021-01-15 | 山东大学 | 1-取代苄基吡唑并嘧啶衍生物及其制备方法与应用 |
WO2021089791A1 (en) | 2019-11-08 | 2021-05-14 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
CN112961159B (zh) * | 2020-03-05 | 2022-07-01 | 四川大学华西医院 | 氨基嘧啶并吡唑/吡咯类衍生物及其制备方法和用途 |
US20240100172A1 (en) | 2020-12-21 | 2024-03-28 | Hangzhou Jijing Pharmaceutical Technology Limited | Methods and compounds for targeted autophagy |
AU2022297176A1 (en) | 2021-06-25 | 2024-01-04 | Korea Research Institute Of Chemical Technology | Novel bifunctional heterocyclic compound having btk degradation function via ubiquitin proteasome pathway, and use thereof |
KR102637915B1 (ko) | 2021-06-25 | 2024-02-19 | 한국화학연구원 | 유비퀴틴 프로테오좀 경로를 통해 비티케이 분해작용을 가지는 신규한 이작용성 헤테로사이클릭 화합물과 이의 용도 |
WO2023050007A1 (en) * | 2021-09-29 | 2023-04-06 | Repare Therapeutics Inc. | N-(5-substituted-[(1,3,4-thiadiazolyl) or (thiazolyl)])(substituted)carboxamide compounds and use thereof for inhibiting human polymerase theta |
CN114213416B (zh) * | 2021-11-05 | 2023-06-06 | 杭州医学院 | 一种恶唑并[4,5-b]吡啶结构的不可逆BTK抑制剂及其应用 |
CN113968860B (zh) * | 2021-11-05 | 2023-06-06 | 杭州医学院 | 一种可逆btk抑制剂及其合成方法和应用 |
WO2024069592A1 (en) * | 2022-09-29 | 2024-04-04 | Repare Therapeutics Inc. | N-(5-substituted-[(l,3,4-thiadiazolyl) or (l,3-thiazolyl)](substituted)carboxamide compounds, pharmaceutical compositions, and methods of preparing the amide compounds and of their use |
Family Cites Families (96)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH01167840A (ja) | 1987-12-24 | 1989-07-03 | Konica Corp | 新規な写真用シアンカプラー |
GB9226855D0 (en) | 1992-12-23 | 1993-02-17 | Erba Carlo Spa | Vinylene-azaindole derivatives and process for their preparation |
US6326469B1 (en) | 1994-04-22 | 2001-12-04 | Sugen, Inc. | Megakaryocytic protein tyrosine kinases |
US5593997A (en) | 1995-05-23 | 1997-01-14 | Pfizer Inc. | 4-aminopyrazolo(3-,4-D)pyrimidine and 4-aminopyrazolo-(3,4-D)pyridine tyrosine kinase inhibitors |
CH690773A5 (de) | 1996-02-01 | 2001-01-15 | Novartis Ag | Pyrrolo(2,3-d)pyrimide und ihre Verwendung. |
WO1997049706A1 (en) | 1996-06-25 | 1997-12-31 | Novartis Ag | SUBSTITUTED 7-AMINO-PYRROLO[3,2-d]PYRIMIDINES AND THE USE THEREOF |
PL335685A1 (en) | 1997-03-19 | 2000-05-08 | Basf Ag | Pyrrole[2,3-d]pyrimidines and their application as inhibitors of tyrosine kinase |
US6303652B1 (en) | 1998-08-21 | 2001-10-16 | Hughes Institute | BTK inhibitors and methods for their identification and use |
ATE269295T1 (de) | 1998-04-17 | 2004-07-15 | Parker Hughes Inst | Btk inhibitoren und verfahren zur identifizierung und verwendung |
US6335155B1 (en) | 1998-06-26 | 2002-01-01 | Sunesis Pharmaceuticals, Inc. | Methods for rapidly identifying small organic molecule ligands for binding to biological target molecules |
US6998233B2 (en) | 1998-06-26 | 2006-02-14 | Sunesis Pharmaceuticals, Inc. | Methods for ligand discovery |
US20050287596A9 (en) | 1998-06-26 | 2005-12-29 | Braisted Andrew C | Novel ligands and libraries of ligands |
US6713474B2 (en) | 1998-09-18 | 2004-03-30 | Abbott Gmbh & Co. Kg | Pyrrolopyrimidines as therapeutic agents |
CZ2001960A3 (cs) | 1998-09-18 | 2001-10-17 | Basf Aktiengesellschaft | Pyrrolopyrimidiny jako inhibitory protein kinasy |
US6306897B1 (en) | 1999-03-19 | 2001-10-23 | Parker Hughes Institute | Calanolides for inhibiting BTK |
US6921763B2 (en) | 1999-09-17 | 2005-07-26 | Abbott Laboratories | Pyrazolopyrimidines as therapeutic agents |
DK1212327T3 (da) | 1999-09-17 | 2003-12-15 | Abbott Gmbh & Co Kg | Pyrazolopyrimidiner som terapeutiske midler |
JP5036112B2 (ja) | 1999-10-06 | 2012-09-26 | ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド | チロシンキナーゼのインヒビターとして有益な複素環化合物 |
US6506769B2 (en) | 1999-10-06 | 2003-01-14 | Boehringer Ingelheim Pharmaceuticals, Inc. | Heterocyclic compounds useful as inhibitors of tyrosine kinases |
AU4508601A (en) | 1999-11-30 | 2001-06-18 | Parker Hughes Institute | Inhibitors of collagen-induced platelet aggregation |
EP1246829A1 (en) | 1999-12-17 | 2002-10-09 | Ariad Pharmaceuticals, Inc. | Novel heterocycles |
GB0005345D0 (en) | 2000-03-06 | 2000-04-26 | Mathilda & Terence Kennedy Ins | Methods of treating sepsis septic shock and inflammation |
AU2000240570A1 (en) | 2000-03-29 | 2001-10-08 | Knoll Gesellschaft Mit Beschraenkter Haftung | Pyrrolopyrimidines as tyrosine kinase inhibitors |
HUP0303656A3 (en) | 2000-10-23 | 2006-03-28 | Bristol Myers Squibb Co | Modulators of bruton's tyrosine kinase, their identification and use |
AU2002232492A1 (en) | 2000-12-06 | 2002-06-18 | Pharmacia Corporation | Rapidly dispersing pharmaceutical composition comprising effervescent agents |
MXPA03008560A (es) | 2001-03-22 | 2004-06-30 | Abbot Gmbh & Co Kg | Pirazolopirimidinas como agentes terapeuticos. |
US8306897B2 (en) | 2001-05-04 | 2012-11-06 | Stockshield, Inc. | Method and system for insuring against investment loss |
US20030114467A1 (en) | 2001-06-21 | 2003-06-19 | Shakespeare William C. | Novel pyrazolo- and pyrrolo-pyrimidines and uses thereof |
CA2450777C (en) | 2001-08-10 | 2013-04-09 | Novartis Ag | Use of c-src inhibitors alone or in combination with sti571 for the treatment of leukaemia |
WO2003016338A1 (en) | 2001-08-15 | 2003-02-27 | Parker Hughes Institute | Crystal structure of the btk kinase domain |
JP4391237B2 (ja) | 2001-11-21 | 2009-12-24 | サネシス ファーマシューティカルズ, インコーポレイテッド | リガンド発見のための方法 |
US20050084905A1 (en) | 2002-03-21 | 2005-04-21 | Prescott John C. | Identification of kinase inhibitors |
GB2388594A (en) | 2002-05-16 | 2003-11-19 | Bayer Ag | Imidazo-triazine PDE 4 inhibitors |
JP2005536533A (ja) | 2002-08-08 | 2005-12-02 | ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド | 置換ベンゾイミダゾール化合物 |
GB0303910D0 (en) | 2003-02-20 | 2003-03-26 | Merck Sharp & Dohme | Therapeutic agents |
WO2005000197A2 (en) | 2003-04-11 | 2005-01-06 | The Regents Of The University Of California | Selective serine/threonine kinase inhibitors |
WO2004100868A2 (en) | 2003-04-23 | 2004-11-25 | Abbott Laboratories | Method of treating transplant rejection |
EP1473039A1 (en) | 2003-05-02 | 2004-11-03 | Centre National De La Recherche Scientifique (Cnrs) | Use of inhibitors and antisense oligonucleotides of BTK for the treatment of proliferative mastocytosis |
WO2005014599A1 (en) | 2003-06-04 | 2005-02-17 | Cellular Genomics, Inc. | Imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of bruton’s tyrosine kinase by such compounds |
WO2005005429A1 (en) | 2003-06-30 | 2005-01-20 | Cellular Genomics, Inc. | Certain heterocyclic substituted imidazo[1,2-a]pyrazin-8-ylamines and methods of inhibition of bruton’s tyrosine kinase by such compounds |
CN1897950A (zh) | 2003-10-14 | 2007-01-17 | 惠氏公司 | 稠合芳基和杂芳基衍生物及其使用方法 |
SG132683A1 (en) | 2003-10-15 | 2007-06-28 | Osi Pharm Inc | Imidazopyrazine tyrosine kinase inhibitors |
US20070196395A1 (en) | 2003-12-12 | 2007-08-23 | Mackerell Alexander | Immunomodulatory compounds that target and inhibit the py'binding site of tyrosene kinase p56 lck sh2 domain |
BRPI0418031A (pt) | 2003-12-22 | 2007-04-17 | Gilead Sciences Inc | inibidores de quinase fosfonato-substituìdos |
AU2005228845A1 (en) | 2004-01-26 | 2005-10-13 | Vertex Pharmaceuticals Incorporated | Compositions useful as inhibitors of protein kinases |
CA2553724A1 (en) | 2004-02-03 | 2005-08-18 | Abbott Laboratories | Aminobenzoxazoles as therapeutic agents |
ITMI20041314A1 (it) | 2004-06-30 | 2004-09-30 | Nuvera Fuel Cells Europ Srl | Dispositivo di raffreddamento per celle a combustibili a membrana |
TW200613306A (en) | 2004-07-20 | 2006-05-01 | Osi Pharm Inc | Imidazotriazines as protein kinase inhibitors |
EP1794137A4 (en) | 2004-09-27 | 2009-12-02 | Kosan Biosciences Inc | SPECIFIC KINASE INHIBITORS |
KR20070063562A (ko) | 2004-09-28 | 2007-06-19 | 얀센 파마슈티카 엔.브이. | 치환 디피페리딘 ccr2 길항제 |
CA2587192A1 (en) | 2004-11-10 | 2006-05-18 | Cgi Pharmaceuticals, Inc. | Imidazo[1 , 2-a] pyrazin-8-ylamines useful as modulators of kinase activity |
GB0425035D0 (en) | 2004-11-12 | 2004-12-15 | Novartis Ag | Organic compounds |
KR100735639B1 (ko) | 2004-12-29 | 2007-07-04 | 한미약품 주식회사 | 암세포 성장 억제 효과를 갖는 퀴나졸린 유도체 및 이의제조방법 |
KR101357524B1 (ko) | 2005-03-10 | 2014-02-03 | 질레드 코네티컷 인코포레이티드 | 특정 치환된 아미드, 그의 제조 방법, 및 사용 방법 |
WO2006124462A2 (en) | 2005-05-13 | 2006-11-23 | Irm, Llc | Compounds and compositions as protein kinase inhibitors |
RS52010B (en) | 2005-06-22 | 2012-04-30 | Plexxikon Inc. | DERIVATI PIROLO [2, 3-B] PIRIDINA KAO INHIBITORI PROTEIN KINAZE |
EP1957491A2 (en) | 2005-11-12 | 2008-08-20 | Boehringer Ingelheim International GmbH | Pyrrolo (2,3-b) pyridine derivatives useful as tec kinase inhibitors |
RU2008133161A (ru) | 2006-01-13 | 2010-02-20 | Фармасайкликс, Инк. (Us) | Ингибиторы тирозин киназ и их применение |
EP2027087A2 (en) | 2006-05-18 | 2009-02-25 | MannKind Corporation | Intracellular kinase inhibitors |
KR101315610B1 (ko) | 2006-09-22 | 2013-10-10 | 파마시클릭스, 인코포레이티드 | 브루톤 티로신 키나제 억제제 |
CA2668286C (en) | 2006-11-03 | 2014-09-16 | Pharmacyclics, Inc. | Bruton's tyrosine kinase activity probe and method of using |
NL2000640C2 (nl) | 2007-03-05 | 2008-09-08 | Stichting Wetsus Ct Of Excelle | Werkwijze en systeem voor het zuiveren van een vloeistof. |
CA2874756C (en) | 2007-03-28 | 2018-05-29 | Pharmacyclics, Inc. | Inhibitors of bruton's tyrosine kinase |
US20120065201A1 (en) | 2007-03-28 | 2012-03-15 | Pharmacyclics, Inc. | Inhibitors of bruton's tyrosine kinase |
US20120101113A1 (en) | 2007-03-28 | 2012-04-26 | Pharmacyclics, Inc. | Inhibitors of bruton's tyrosine kinase |
US7989465B2 (en) | 2007-10-19 | 2011-08-02 | Avila Therapeutics, Inc. | 4,6-disubstituted pyrimidines useful as kinase inhibitors |
US8426441B2 (en) | 2007-12-14 | 2013-04-23 | Roche Palo Alto Llc | Inhibitors of bruton's tyrosine kinase |
US20150152115A1 (en) | 2007-12-27 | 2015-06-04 | Pharmacyclics, Inc. | Inhibitors of bruton's tyrosine kinase |
ES2660418T3 (es) | 2008-07-16 | 2018-03-22 | Pharmacyclics Llc | Inhibidores de la tirosina quinasa de Bruton para el tratamiento de tumores sólidos |
WO2010028236A1 (en) | 2008-09-05 | 2010-03-11 | Avila Therapeutics, Inc. | Algorithm for designing irreversible inhibitors |
US8426428B2 (en) | 2008-12-05 | 2013-04-23 | Principia Biopharma, Inc. | EGFR kinase knockdown via electrophilically enhanced inhibitors |
DK2473049T3 (en) | 2009-09-04 | 2019-04-01 | Biogen Ma Inc | INHIBITORS OF BRUTON'S TYROSINKINASE |
EP2475375A4 (en) | 2009-09-09 | 2013-02-20 | Avila Therapeutics Inc | PI3 KINASE INHIBITORS AND USES THEREOF |
US7718662B1 (en) | 2009-10-12 | 2010-05-18 | Pharmacyclics, Inc. | Pyrazolo-pyrimidine inhibitors of bruton's tyrosine kinase |
EP2578585B1 (en) | 2010-05-31 | 2016-07-20 | ONO Pharmaceutical Co., Ltd. | Purinone derivative as btk kinase inhibitor |
CN107898791A (zh) | 2010-06-03 | 2018-04-13 | 药品循环有限责任公司 | 布鲁顿酪氨酸激酶(btk)抑制剂的应用 |
NZ627709A (en) | 2010-06-23 | 2014-12-24 | Hanmi Science Co Ltd | Novel fused pyrimidine derivatives for inhibition of tyrosine kinase activity |
BR112013028846B1 (pt) | 2011-05-17 | 2021-12-07 | Principia Biopharma Inc | Composto ou sal farmaceuticamente aceitável do mesmo, respectivos usos, processo de preparação, intermediários e composição farmacêutica |
PL2710007T3 (pl) | 2011-05-17 | 2020-06-01 | The Regents Of The University Of California | Inhibitory kinazy |
US9376438B2 (en) * | 2011-05-17 | 2016-06-28 | Principia Biopharma, Inc. | Pyrazolopyrimidine derivatives as tyrosine kinase inhibitors |
BR112013033534A2 (pt) | 2011-06-28 | 2017-02-07 | Pharmacyclics Inc | métodos e composições para inibição de reabsorção de osso |
KR20140048968A (ko) | 2011-07-13 | 2014-04-24 | 파마시클릭스, 인코포레이티드 | 브루톤형 티로신 키나제의 억제제 |
EP2548877A1 (en) | 2011-07-19 | 2013-01-23 | MSD Oss B.V. | 4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors |
US8377946B1 (en) | 2011-12-30 | 2013-02-19 | Pharmacyclics, Inc. | Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors |
US8501724B1 (en) | 2012-01-31 | 2013-08-06 | Pharmacyclics, Inc. | Purinone compounds as kinase inhibitors |
CN110354132A (zh) | 2012-06-04 | 2019-10-22 | 药品循环有限责任公司 | 布鲁顿酪氨酸激酶抑制剂的晶形 |
CN104487441B (zh) | 2012-06-18 | 2018-06-01 | 普林斯匹亚生物制药公司 | 有用于治疗癌症和自身免疫性疾病的可逆的共价吡咯并嘧啶或吡唑并嘧啶 |
US9604988B2 (en) | 2012-07-27 | 2017-03-28 | Riken | Agent for treating or inhibiting recurrence of acute myeloid leukemia |
WO2014022569A1 (en) | 2012-08-03 | 2014-02-06 | Principia Biopharma Inc. | Treatment of dry eye |
CN104854107A (zh) | 2012-11-15 | 2015-08-19 | 药品循环公司 | 作为激酶抑制剂的吡咯并嘧啶化合物 |
US8957080B2 (en) | 2013-04-09 | 2015-02-17 | Principia Biopharma Inc. | Tyrosine kinase inhibitors |
AR097204A1 (es) | 2013-08-02 | 2016-02-24 | Pharmacyclics Inc | Métodos de tratamiento de tumores sólidos |
MX2016005283A (es) | 2013-10-25 | 2017-02-20 | Pharmacyclics Llc | Tratamiento que utiliza inhibidores de tirosina quinasa de bruton e inmunoterapia. |
CN106008515A (zh) | 2014-01-29 | 2016-10-12 | 苏州晶云药物科技有限公司 | 依鲁替尼的新晶型及其制备方法 |
WO2015127261A1 (en) | 2014-02-21 | 2015-08-27 | Pharmacyclics, Inc. | Biomarkers for predicting response of dlbcl to treatment with ibrutinib |
US9885086B2 (en) | 2014-03-20 | 2018-02-06 | Pharmacyclics Llc | Phospholipase C gamma 2 and resistance associated mutations |
-
2014
- 2014-09-29 CR CR20160203A patent/CR20160203A/es unknown
- 2014-09-29 US US14/500,897 patent/US9624224B2/en active Active
- 2014-09-29 EA EA201690618A patent/EA201690618A1/ru unknown
- 2014-09-29 PE PE2016000427A patent/PE20160560A1/es not_active Application Discontinuation
- 2014-09-29 CN CN201480065396.6A patent/CN105764896A/zh active Pending
- 2014-09-29 EP EP14848332.4A patent/EP3052486A1/en not_active Withdrawn
- 2014-09-29 CA CA2925124A patent/CA2925124A1/en not_active Abandoned
- 2014-09-29 JP JP2016545269A patent/JP2016531941A/ja active Pending
- 2014-09-29 KR KR1020167010963A patent/KR20160062103A/ko not_active Application Discontinuation
- 2014-09-29 WO PCT/US2014/058132 patent/WO2015048689A1/en active Application Filing
- 2014-09-29 TN TN2016000094A patent/TN2016000094A1/en unknown
- 2014-09-29 MA MA38961A patent/MA38961A1/fr unknown
- 2014-09-29 BR BR112016006978A patent/BR112016006978A2/pt not_active Application Discontinuation
- 2014-09-29 SG SG11201602421VA patent/SG11201602421VA/en unknown
- 2014-09-29 AU AU2014324532A patent/AU2014324532A1/en not_active Abandoned
- 2014-09-30 TW TW103134098A patent/TW201546061A/zh unknown
- 2014-09-30 AR ARP140103633A patent/AR097862A1/es unknown
-
2016
- 2016-03-08 IL IL244492A patent/IL244492A0/en unknown
- 2016-03-29 DO DO2016000071A patent/DOP2016000071A/es unknown
- 2016-03-29 PH PH12016500575A patent/PH12016500575A1/en unknown
- 2016-10-19 US US15/297,898 patent/US20170050970A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
PE20160560A1 (es) | 2016-06-09 |
CR20160203A (es) | 2016-08-31 |
MA38961A1 (fr) | 2018-05-31 |
WO2015048689A1 (en) | 2015-04-02 |
EA201690618A1 (ru) | 2016-09-30 |
DOP2016000071A (es) | 2016-09-15 |
AU2014324532A1 (en) | 2016-04-21 |
PH12016500575A1 (en) | 2016-07-25 |
US20170050970A1 (en) | 2017-02-23 |
AR097862A1 (es) | 2016-04-20 |
TW201546061A (zh) | 2015-12-16 |
EP3052486A1 (en) | 2016-08-10 |
SG11201602421VA (en) | 2016-04-28 |
US9624224B2 (en) | 2017-04-18 |
KR20160062103A (ko) | 2016-06-01 |
TN2016000094A1 (en) | 2017-07-05 |
WO2015048689A8 (en) | 2015-05-07 |
JP2016531941A (ja) | 2016-10-13 |
US20150094319A1 (en) | 2015-04-02 |
IL244492A0 (en) | 2016-04-21 |
CN105764896A (zh) | 2016-07-13 |
CA2925124A1 (en) | 2015-04-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112016006978A2 (pt) | inibidores de tirosina quinase de bruton | |
BR112014018728A8 (pt) | Compostos de purinonas como inibidores de quinase | |
MX2020010412A (es) | Inhibidores de tirosina quinasa de bruton. | |
BR112015011171A2 (pt) | compostos de pirrolopirimidina como inibidores da quinase | |
CY1124436T1 (el) | Δικυκλικες ετεροκυκλικες ενωσεις και χρησεις αυτων στη θεραπεια | |
MX2017015574A (es) | Inhibidores de tirosina quinasa de bruton. | |
TW201613919A (en) | Inhibitors of Bruton's tyrosine kinase | |
NI201500059A (es) | Inhibidores de la tirosina-quinasa de bruton | |
EA202092456A2 (ru) | Комбинированная терапия, включающая ингибитор mdm2 и один или более дополнительных фармацевтически активных агентов, для лечения различных видов рака | |
NI201600071A (es) | Compuestos de inhibidor de autotaxina | |
BR112016029041A8 (pt) | uso de um inibidor de glutaminase, composição farmacêutica e kit farmacêutico | |
EA201691079A1 (ru) | Комбинированная терапия для лечения онкологического заболевания | |
BR112015026021A2 (pt) | terapia de combinação compreendendo um inibidor de tor quinase e n-(3-(5-flúor-2-(4-(2-met-oxietoxi)fenilamino)pirimidin-4-ilamino)fenil)acrilamida para o tratamento de câncer | |
EA201591925A1 (ru) | Терапевтические композиции и их применение | |
BR112015026247A8 (pt) | composto em combinação com um análogo de citidina, composição farmacêutica que os compreende, uso dos mesmos e kit | |
PL410665A1 (pl) | Inhibitory arginazy oraz ich zastosowania terapeutyczne | |
MX2021010041A (es) | Composiciones farmaceuticas que comprenden inhibidores de la proteina quinasa akt. | |
BR112017018198A2 (pt) | inibição da atividade de olig2 | |
EP3581653A3 (en) | Methods and compositions for treating cancer using peptide nucleic acid-based agents | |
TW201613926A (en) | Inhibitors of bruton's tyrosine kinase | |
EA201592012A1 (ru) | Применение флагеллина для улучшенной химиотерапии | |
EA202091908A2 (ru) | Комбинированная терапия для лечения онкологического заболевания |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |